Login / Signup

Telmisartan versus EnalapRil In heart failure with redUced ejection fraction patients with Moderately impaired kidney Functions; randomized controlled trial: "TRIUMF trial".

Ahmed SamirSalma Aboel-NagaAhmed ShehataMagdy Abdelhamid
Published in: The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology (2023)
In patients with HFrEF and CKD, Telmisartan was better tolerated to uptitrate, caused less WRF, less HFH and showed better functional improvement compared to Enalapril. Clinical trial registration This study was prospectively registered on clinicaltrials.gov, with registration number (NCT04736329).
Keyphrases
  • clinical trial
  • study protocol
  • randomized controlled trial
  • heart failure
  • phase ii
  • phase iii
  • chronic kidney disease
  • open label
  • left ventricular
  • atrial fibrillation
  • cardiac resynchronization therapy